Active Substance: Factor VIII Inhibitor Bypassing Activity (in human plasma protein) 500 Units/Vial.
Overview
Welcome to Dwaey, specifically on FEIBA 500 U page.
This medicine contains an important and useful components, as it consists of
Factor VIII Inhibitor Bypassing Activity (in human plasma protein) 500 Units/Vialis available in the market in concentration
Factor VIII
Risk of intravascular haemolysis in patients with blood groups A, B, or AB receiving high doses or repeated doses of factor VIII preparations. Risk of transmission of some viral infections especially hepatitis B and C. Dose requirement may vary in patients with factor VIII inhibitors; thus optimal treatment should be based on clinical response. Monitor platelet counts regularly during treatment. Pregnancy, lactation. Lactation: Excretion in milk unknown; use with caution
Haemophilia A, Haemorrhage
Hypersensitivity
Allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion.
3
Factor VIII is required for clot formation and maintenance of haemostasis. It activates factor X in conjunction with activated factor IX. Activated factor X then converts prothrombin to thrombin, which converts fibrinogen to fibrin, and forms a stable clot with factor XIII. Factor VIII is used for replacement therapy in patients with haemophilia A.
Information not available
Information not available